Rein Therapeutics Files 8‑K, Publishes LTI‑03 Presentation

What Happened
Rein Therapeutics, Inc. (RNTX) filed an 8‑K on September 4, 2026 (Item 7.01) to disclose that it published a presentation concerning its LTI‑03 product candidate on its investor relations website. The company attached the presentation as Exhibit 99.1 to the filing and made the materials available at https://ir.reintx.com/events-presentations.

Key Details

• Filing date: September 4, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Presentation subject: LTI‑03 product candidate (presentation attached as Exhibit 99.1).
• Location: Posted on Rein Therapeutics’ investor relations “Events & Presentations” web page.
• Administrative exhibit note (Item 9.01): presentation materials filed electronically; interactive cover page (Inline XBRL) included.

Why It Matters
This disclosure communicates company information about LTI‑03 to the public under Regulation FD, ensuring investors and the market have equal access to the presentation materials. For investors, the filing signals that Rein is publicly sharing updates on a clinical/product program (LTI‑03); reviewing the attached presentation can provide more detail on development status, timelines, or data that may be relevant to investment decisions. The 8‑K itself does not include new financial results or executive changes.